1. Home
  2. SRCE vs PHVS Comparison

SRCE vs PHVS Comparison

Compare SRCE & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 1st Source Corporation

SRCE

1st Source Corporation

HOLD

Current Price

$76.25

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$33.17

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRCE
PHVS
Founded
1863
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
SRCE
PHVS
Price
$76.25
$33.17
Analyst Decision
Hold
Buy
Analyst Count
4
11
Target Price
$74.50
$41.82
AVG Volume (30 Days)
99.5K
297.8K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
2.37%
N/A
EPS Growth
19.59
N/A
EPS
1.63
N/A
Revenue
N/A
N/A
Revenue This Year
$10.29
N/A
Revenue Next Year
$3.16
N/A
P/E Ratio
$47.64
N/A
Revenue Growth
N/A
N/A
52 Week Low
$56.89
$16.72
52 Week High
$79.08
$33.33

Technical Indicators

Market Signals
Indicator
SRCE
PHVS
Relative Strength Index (RSI) 55.10 62.11
Support Level $71.36 $24.73
Resistance Level N/A $33.33
Average True Range (ATR) 1.45 1.51
MACD 0.18 0.14
Stochastic Oscillator 55.42 88.69

Price Performance

Historical Comparison
SRCE
PHVS

About SRCE 1st Source Corporation

1st Source Corp provides specialized financing services for construction equipment, aircraft, and vehicle types through its Specialty Finance activities. The company offers commercial, small business, agricultural, and real estate loans, along with commercial leasing, treasury management, and payment services, including Fedwires, ACH, and merchant services. It also provides Renewable Energy Financing for commercial solar projects, a full range of consumer banking products, Trust and Wealth Advisory Services, and insurance products. The company operates in the commercial banking segment, which provides commercial and consumer banking services, trust and wealth advisory services, and insurance to individual and business clients across its markets.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: